Altamira Therapeutics : Corporate Presentation Winter 2023

DELIVERING RNA - BEYOND THE LIVER

Investor Presentation

Winter 2023

Forward-Looking Statements

This presentation may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Altamira Therapeutics' strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may", "might", "will", "should", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "projects", "potential", "outlook" or "continue", or the negative of these terms or other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, the success of the continued commercialization of Bentrio and success of strategic transactions, including licensing or partnering, with respect to Bentrio or any other legacy assets, Altamira Therapeutics' need for and ability to raise substantial additional funding to continue the development of its product candidates, the timing and conduct of clinical trials of Altamira Therapeutics' product candidates, the clinical utility of Altamira Therapeutics' product candidates, the timing or likelihood of regulatory filings and approvals, Altamira Therapeutics' intellectual property position and Altamira Therapeutics' financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Altamira Therapeutics' capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption "Risk Factors" in Altamira Therapeutics' Annual Report on Form 20-F for the year ended December 31, 2022, and in Altamira Therapeutics' other filings with the SEC, which are available free of charge on the Securities Exchange Commission's website at: www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Altamira Therapeutics or to persons acting on behalf of Altamira Therapeutics are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Altamira Therapeutics does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law.

NASDAQ: CYTO

2

Company Overview

Disruptive, Proprietary RNA Delivery Technology Platform

OligoPhore™ (siRNA)	• Proprietary 21 amino acid peptide for efficient delivery
SemaPhore™ (mRNA)	of RNA into target cells (nanoparticles)
Platforms	• Non-hepatic targets, unlike mainstream technology
RNA Market Taking Off	• Rapidly growing number of RNA therapeutics
	• Active M&A, licensing environment
	• Delivery platforms for partnering with pharma &
	biotech
Two Novel, Early-Stage	• KRAS-driven cancers (AM-401) - IND expected in 2025
Drug Candidates	• Rheumatoid Arthritis (AM-411) - IND expected in 2025
Divesting / Partnering	• Unlock intrinsic value of inner ear & OTC assets
Legacy Assets	• Extra, non-dilutive funding potential

NASDAQ: CYTO

3

How Our Technology Works

OligoPhore/SemaPhore are nanoparticles comprising a proprietary peptide +

RNA payload designed to enable safe and effective delivery by systemic administration.

Stability	RNA complexed in nanoparticle format and only released inside
of cells after uptake

Extrahepatic delivery

Not sequestered in liver as is common with conventional RNA- based therapies; permeates inflamed pathological tissues (passive targeting)

Endosomal escape

Efficient release within target cell, payload reported at 90+% available in vitro studies vs. 1-2% with current technologies, observed in murine preclinical studies

Selectivity	Acts on targets in diseased tissues only
Safety	No cellular or adaptive immune responsivity to nanoparticle
components or RNA after multiple serial doses, and no organ
	toxicities in mice
	NASDAQ: CYTO		4

RNA Delivery is One of the Key Challenges

Exemplary listing of companies active in RNA therapeutics and delivery (list not exhaustive)

Silence gene expression

• Short interfering RNA (siRNA)
• Antisense oligonucleotides (ASOs)

Promote protein expression

• Messenger RNA (mRNA)

Deliver RNA therapeutic to target

• Lipid nanoparticles
• Virus-basedvectors
• Ligand conjugates
• Peptide-basednanoparticles

$606 million

$6.8 million

$342 million

$523 million

$3.3 billion*

$170 million

*Represents valuation of the company derived from 2021 acquisition	NASDAQ: CYTO
Figures are sourced from Yahoo Finance as of August 18, 2023

5

Disruptive Technology Growth Opportunities

Frontiers in Bioengineering

and Biotechnology,

March 2021

High specificity

Cost effective

Relatively simple to manufacture

Can target previously undruggable pathways

Disruptive technology

mRNA Vaccines & Therapeutics

Global Sales

$120B			$12B
$100B			$10B
	$101.3B
$80B			$8B
$60B			$6B
$46.7B
$40B		$4B
$20B			$2B
$0B			$0B

2021 2026

siRNA Therapeutics

Global Sales

$11.0B

$4.9B

2021 2026

STRONG GROWTH-STARTING IN 2018

ONLY THE BEGINNING!

*Research and Markets; Allied Market Research

NASDAQ: CYTO

6

Corporate RNA Strategy

Leverage versatility of technology

• Demonstrated to work in multiple

disease areas (tested in 17 models….)

OligoPhore has been tested in vivo…

• Suitable for siRNA, mRNA, ASOs,

circular RNA

Particularly well-suitedfor

indications in oncology and inflammatory disorders

Selecting two therapeutic indications to showcase technology

• KRAS driven cancers - AM-401
•	Rheumatoid arthritis - AM-411
•	Partner upon IND or Phase 1

• Pancreatic and colorectal cancer (KRAS)
• Ovarian cancer (TAM: AXL)
• Lung cancer (ETV-2)
• Metastatic melanoma (NF-κB)
• Adult T cell leukemia/lymphoma (NF- κB)
• Sarcoma (MYCT-1)
• • Sacroma and breast cancer (MYCT-1)

• Necrotizing enterocolitis (NF-κB)
• Rheumatoid and osteoarthritis (NF-κB)
• Atherosclerosis (JNK2)
• Metabolic syndrome/Obesity (ASXL2)
• Aortic aneurysm (NF-κB)
• Osteoarthritis (NF-κB)

Leverage technology platform

SemaPhore™ has been tested in vivo…

through out-licensing

• Become drug delivery platform company
• First collaboration: Heqet Therapeutics

• Osteoarthritis (WNT16)
• Atherosclerosis (p27Kip1)
• Aortic aneurysm (SOD2)

• Osteoarthritis (DNMT3B)
• Tumor microenvironment (ZBTB46)

NASDAQ: CYTO

7

AM-401: Stop the "Beating Heart" of Tumors

Knock down various KRAS mutations with polyKRASmut OligoPhore nanoparticles

to inhibit cell proliferation in KRAS driven colorectal, pancreatic, or non-small cell lung cancer.

Many mutations known, G12D, G12V,	OligoPhore polyKRASmut
and G12C accounting for >50%	siRNA transfects tumor cells,
	not healthy or uninvolved cells

• Mutated KRAS may cause cancer to grow
• Found in 1/5 of all human cancers, particularly in:
• • Pancreatic cancer (85-90%)
  • Colorectal cancer (40%)
  • Non-smallcell lung cancer (30-35%)
• 150,000 cases diagnosed in US p.a.
• ~1M deaths per year world-wide
• Considered "undruggable" for decades

• Scrambled siRNA nanoparticle
• polyKRASmut nanoparticle

OligoPhore polyKRASmut significantly reduces pancreatic tumor volume growth

KPC pancreatic tumor model in mice; Strand et al., 2019

*KPC pancreatic tumor model in mice; Strand et al., 2019

NASDAQ: CYTO

8

AM-401

KRAS driven cancer

IND targeted for 2023

High unmet medical need - most aggressive tumors

Small molecule G12C inhibitors approved in NSCLC

• Sotorasib (Lumakras, Amgen), Adagrasib (Krazati, Mirati)

Multiple other small molecule inhibitors under development (G12C, G12D…), but few competing RNA projects (G12D or KRAS modulators)

AM-401 KEY DIFFERENTIATING FACTORS

polyKRASmut allows to target different mutations and is thus polyvalent

Blocking production of KRAS by degrading mRNA to cause less resistance than inhibition of KRAS

Small molecule inhibitors have significant side effects, particularly when combined with other agents

OligoPhore targets specifically tumor cells

NASDAQ: CYTO

9

AM-411: Block Inflammation in Rheumatoid Arthritis

Knock down NF-κB (p65),

a key checkpoint in RA inflammation.

• Chronic autoimmune disease
• Causes joint swelling and pain
• • Reduced QoL and productivity
• Affects 1 out of 28 women / 59 men
• No cure available, but various treatment options:
• • Disease-modifyinganti-rheumatic drugs (DMARDs)
  • Non-steroidalanti-inflammatory drugs (NSAIDs)
  • Corticosteroids
• Major shortcomings of therapies:
• • Drug resistance (up to 50% of patients)
  • Systemic adverse reactions (e.g., rash, hair loss, altered liver function, low blood cell counts, nausea, weight loss, increased infections, and neuropathy)

OligoPhore p65 stabilizes ankle swelling and reduces arthritis score

• Control
• Peptide nanoparticle
• Peptide + p65 nanoparticle

OligoPhore p65 reduces inflammation and protects against bone erosion

Collagen-antibody induced arthritis model in mice, Zhou et al., 2014.

NASDAQ: CYTO

10